<p>NBT Bank N A NY 在最近向证券交易委员会（SEC）披露的文件中表示，在第二季度减少了对百时美施贵宝公司（NYSE:BMY - 免费报告）21.4% 的持股。该公司在季度内出售了 16,600 股后，持有 60,930 股生物制药公司的股票。在最近的报告期结束时，NBT Bank N A NY 在百时美施贵宝的持股价值为 2,820,000 美元。</p>
<p>获取 <strong>百时美施贵宝</strong> 的提醒：</p>
<ul>
<li>不要被反弹所迷惑：市场风暴尚未结束</li>
</ul>
<p>其他几家对冲基金最近也增加或减少了对 BMY 的持股。先锋集团（Vanguard Group Inc.）在第一季度将其在百时美施贵宝的持股增加了 0.8%。先锋集团目前持有 191,403,004 股生物制药公司的股票，价值为 11,673,669,000 美元，此前在该期间又购买了 1,458,488 股。查尔斯·施瓦布投资管理公司（Charles Schwab Investment Management Inc.）在第一季度将其在百时美施贵宝的持股增加了 0.5%。查尔斯·施瓦布投资管理公司目前持有 60,606,905 股生物制药公司的股票，价值为 3,696,415,000 美元，此前在该期间又收购了 306,430 股。纽约梅隆银行（Bank of New York Mellon Corp）在第一季度将其在百时美施贵宝的持股增加了 8.6%。纽约梅隆银行目前持有 26,865,073 股生物制药公司的股票，价值为 1,638,501,000 美元，此前在该期间又收购了 2,131,205 股。北方信托公司（Northern Trust Corp）在第一季度将其在百时美施贵宝的持股增加了 5.3%。北方信托公司目前持有 25,974,504 股生物制药公司的股票，价值为 1,584,185,000 美元，此前在该期间又购买了 1,316,144 股。最后，威灵顿管理集团（Wellington Management Group LLP）在第一季度将其在百时美施贵宝的持股增加了 297.0%。威灵顿管理集团目前持有 23,728,443 股生物制药公司的股票，价值为 1,447,198,000 美元，此前在该期间又购买了 17,750,938 股。机构投资者和对冲基金持有该公司 76.41% 的股票。</p>
<h2>百时美施贵宝股价下跌 1.1%</h2>
<p>BMY 周三开盘价为 44.63 美元。该公司的债务与股本比率为 2.54，流动比率为 1.21，速动比率为 1.11。该公司的市值为 908.4 亿美元，市盈率为 18.00，市盈增长比率为 2.31，贝塔值为 0.33。该公司的 50 日简单移动平均线为 46.27 美元，200 日简单移动平均线为 48.36 美元。百时美施贵宝公司的 52 周最低价为 42.96 美元，52 周最高价为 63.33 美元。</p>
<ul>
<li>MarketBeat 周回顾 – 02/03 - 02/07</li>
</ul>
<p>百时美施贵宝（NYSE:BMY - 获取免费报告）最近在 7 月 31 日（星期四）发布了季度财报。该生物制药公司报告本季度每股收益为 1.46 美元，超出分析师一致预期的 1.07 美元，超出幅度为 0.39 美元。百时美施贵宝的净利润率为 10.58%，股本回报率为 80.04%。该公司本季度的收入为 122.7 亿美元，而一致预期为 113.2 亿美元。在去年同期，该公司每股收益为 2.07 美元。百时美施贵宝本季度的收入较去年同期增长了 0.6%。百时美施贵宝已将其 2025 财年的指引设定为每股收益 6.350-6.650 美元。平均而言，卖方分析师预计百时美施贵宝公司今年将发布每股收益 6.74 美元。</p>
<h2>百时美施贵宝宣布分红</h2>
<p>该公司最近还宣布了一项季度分红，将于 11 月 3 日（星期一）支付。10 月 3 日（星期五）登记在册的股东将获得 0.62 美元的分红。这相当于每年 2.48 美元的分红，收益率为 5.6%。该分红的除息日为 10 月 3 日（星期五）。百时美施贵宝的分红支付比率目前为 100.00%。</p>
<h2>内部人员买卖情况</h2>
<ul>
<li>百时美施贵宝的疲软指引可能创造了机会</li>
</ul>
<p>在其他消息中，执行副总裁 David V. Elkins 在 9 月 2 日（星期二）出售了 56,000 股该股票。股票以平均价格 47.33 美元出售，总交易额为 2,650,480.00 美元。出售完成后，该执行副总裁持有 167,379 股公司股票，价值为 7,922,048.07 美元。这代表其持股减少了 25.07%。该交易已在向证券交易委员会的法律文件中披露，文件可通过此链接获取。内部人士持有公司 0.07% 的股票。</p>
<h2>华尔街分析师观点</h2>
<p>几家研究公司最近对 BMY 发布了报告。大和资本市场（Daiwa Capital Markets）将百时美施贵宝的股票评级从 “跑赢大盘” 下调至 “中性”，并设定了 42.00 美元的目标价。在 8 月 5 日（星期二）的报告中，大和美国（Daiwa America）将百时美施贵宝的股票评级从 “强烈买入” 下调至 “持有”。摩根士丹利（Morgan Stanley）在 7 月 31 日（星期四）的研究报告中重申了对百时美施贵宝的 “持有” 评级。花旗集团（Citigroup）在 8 月 1 日（星期五）的研究报告中将百时美施贵宝的目标价从 51.00 美元下调至 47.00 美元，并对该股票设定了 “中性” 评级。最后，Dbs Bank 在 10 月 2 日（星期四）的研究报告中将百时美施贵宝的股票评级上调至 “适度买入”。一位股票研究分析师对该股票给予了 “强烈买入” 评级，五位分析师给予 “买入” 评级，十五位分析师对该公司的股票给予 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，平均目标价为 57.14 美元。</p>
<p><strong>查看我们关于 BMY 的最新报告</strong></p>
<h2>百时美施贵宝简介</h2>
<p>（免费报告）</p>
<p>百时美施贵宝公司在全球范围内发现、开发、许可、制造、营销、分销和销售生物制药产品。它提供针对血液学、肿瘤学、心血管、免疫学、纤维化和神经科学疾病的产品。公司的产品包括 Eliquis，用于降低非瓣膜性房颤患者中风/全身栓塞的风险，以及治疗深静脉血栓/DVT/肺栓塞/PE；Opdivo，用于多种抗癌适应症，包括膀胱癌、血液癌、结直肠癌、头颈癌、肾细胞癌、肝细胞癌、肺癌、黑色素瘤、胸膜间皮瘤、胃癌和食道癌；Pomalyst/Imnovid 用于多发性骨髓瘤；Orencia 用于活动性类风湿关节炎和银屑病关节炎；Sprycel 用于治疗费城染色体阳性慢性髓性白血病。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们认为比百时美施贵宝更好的股票</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>EA 的 550 亿美元交易引发游戏行业的震荡</li>
<li>什么是股票市场指数，如何使用它们？</li>
<li>这些是第三季度盈利增长的三个热门行业</li>
<li>国会股票交易跟踪</li>
<li>AMD 可能会在此基础上翻倍——得益于其与 OpenAI 的重磅交易</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在百时美施贵宝吗？</h2>
<p>在你考虑百时美施贵宝之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而百时美施贵宝并不在名单上。</p>
<p>虽然百时美施贵宝目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

百时美施贵宝

<p>NBT Bank N A NY 在第二季度减少了对百时美施贵宝公司的持股比例，下降了 21.4%，目前持有 60,930 股，价值 282 万美元。其他对冲基金，包括先锋集团和查尔斯·施瓦布，也调整了他们的持股。百时美施贵宝的股票开盘价为 44.63 美元，市值为 908.4 亿美元。该公司报告第二季度每股收益为 1.46 美元，超出预期，并宣布季度股息为 0.62 美元，收益率为 5.6%。内部人士出售股票的情况被注意到，执行副总裁 David V. Elkins 最近出售了 56,000 股</p>

<p>NBT Bank N A NY lessened its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 21.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 60,930 shares of the biopharmaceutical company's stock after selling 16,600 shares during the quarter. NBT Bank N A NY's holdings in Bristol Myers Squibb were worth $2,820,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>NBT Bank N A NY 在最近向证券交易委员会（SEC）披露的文件中表示，在第二季度减少了对百时美施贵宝公司（NYSE:BMY - 免费报告）21.4% 的持股。该公司在季度内出售了 16,600 股后，持有 60,930 股生物制药公司的股票。在最近的报告期结束时，NBT Bank N A NY 在百时美施贵宝的持股价值为 2,820,000 美元。</p>
</div><p>Get <strong>Bristol Myers Squibb</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>百时美施贵宝</strong> 的提醒：</p>
</div><ul>
<li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>不要被反弹所迷惑：市场风暴尚未结束</li>
</ul>
</div><p>Several other hedge funds have also recently added to or reduced their stakes in BMY. Vanguard Group Inc. boosted its stake in shares of Bristol Myers Squibb by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 191,403,004 shares of the biopharmaceutical company's stock valued at $11,673,669,000 after buying an additional 1,458,488 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Bristol Myers Squibb by 0.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 60,606,905 shares of the biopharmaceutical company's stock worth $3,696,415,000 after acquiring an additional 306,430 shares during the period. Bank of New York Mellon Corp raised its holdings in Bristol Myers Squibb by 8.6% in the 1st quarter. Bank of New York Mellon Corp now owns 26,865,073 shares of the biopharmaceutical company's stock worth $1,638,501,000 after acquiring an additional 2,131,205 shares during the period. Northern Trust Corp increased its holdings in shares of Bristol Myers Squibb by 5.3% during the 1st quarter. Northern Trust Corp now owns 25,974,504 shares of the biopharmaceutical company's stock worth $1,584,185,000 after purchasing an additional 1,316,144 shares during the period. Finally, Wellington Management Group LLP increased its holdings in shares of Bristol Myers Squibb by 297.0% during the 1st quarter. Wellington Management Group LLP now owns 23,728,443 shares of the biopharmaceutical company's stock worth $1,447,198,000 after purchasing an additional 17,750,938 shares during the period. Institutional investors and hedge funds own 76.41% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也增加或减少了对 BMY 的持股。先锋集团（Vanguard Group Inc.）在第一季度将其在百时美施贵宝的持股增加了 0.8%。先锋集团目前持有 191,403,004 股生物制药公司的股票，价值为 11,673,669,000 美元，此前在该期间又购买了 1,458,488 股。查尔斯·施瓦布投资管理公司（Charles Schwab Investment Management Inc.）在第一季度将其在百时美施贵宝的持股增加了 0.5%。查尔斯·施瓦布投资管理公司目前持有 60,606,905 股生物制药公司的股票，价值为 3,696,415,000 美元，此前在该期间又收购了 306,430 股。纽约梅隆银行（Bank of New York Mellon Corp）在第一季度将其在百时美施贵宝的持股增加了 8.6%。纽约梅隆银行目前持有 26,865,073 股生物制药公司的股票，价值为 1,638,501,000 美元，此前在该期间又收购了 2,131,205 股。北方信托公司（Northern Trust Corp）在第一季度将其在百时美施贵宝的持股增加了 5.3%。北方信托公司目前持有 25,974,504 股生物制药公司的股票，价值为 1,584,185,000 美元，此前在该期间又购买了 1,316,144 股。最后，威灵顿管理集团（Wellington Management Group LLP）在第一季度将其在百时美施贵宝的持股增加了 297.0%。威灵顿管理集团目前持有 23,728,443 股生物制药公司的股票，价值为 1,447,198,000 美元，此前在该期间又购买了 17,750,938 股。机构投资者和对冲基金持有该公司 76.41% 的股票。</p>
</div><h2>Bristol Myers Squibb Trading Down 1.1%</h2>
<div class="lb-trans"><h2>百时美施贵宝股价下跌 1.1%</h2>
</div><p>BMY opened at $44.63 on Wednesday. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. The company has a market cap of $90.84 billion, a price-to-earnings ratio of 18.00, a price-to-earnings-growth ratio of 2.31 and a beta of 0.33. The firm has a 50 day simple moving average of $46.27 and a 200 day simple moving average of $48.36. Bristol Myers Squibb Company has a fifty-two week low of $42.96 and a fifty-two week high of $63.33.</p>
<div class="lb-trans"><p>BMY 周三开盘价为 44.63 美元。该公司的债务与股本比率为 2.54，流动比率为 1.21，速动比率为 1.11。该公司的市值为 908.4 亿美元，市盈率为 18.00，市盈增长比率为 2.31，贝塔值为 0.33。该公司的 50 日简单移动平均线为 46.27 美元，200 日简单移动平均线为 48.36 美元。百时美施贵宝公司的 52 周最低价为 42.96 美元，52 周最高价为 63.33 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 02/03 - 02/07</li>
</ul>
</div><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. During the same period in the previous year, the firm posted $2.07 earnings per share. Bristol Myers Squibb's revenue for the quarter was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.</p>
<div class="lb-trans"><p>百时美施贵宝（NYSE:BMY - 获取免费报告）最近在 7 月 31 日（星期四）发布了季度财报。该生物制药公司报告本季度每股收益为 1.46 美元，超出分析师一致预期的 1.07 美元，超出幅度为 0.39 美元。百时美施贵宝的净利润率为 10.58%，股本回报率为 80.04%。该公司本季度的收入为 122.7 亿美元，而一致预期为 113.2 亿美元。在去年同期，该公司每股收益为 2.07 美元。百时美施贵宝本季度的收入较去年同期增长了 0.6%。百时美施贵宝已将其 2025 财年的指引设定为每股收益 6.350-6.650 美元。平均而言，卖方分析师预计百时美施贵宝公司今年将发布每股收益 6.74 美元。</p>
</div><h2>Bristol Myers Squibb Announces Dividend</h2>
<div class="lb-trans"><h2>百时美施贵宝宣布分红</h2>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be paid a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.6%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb's dividend payout ratio is presently 100.00%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，将于 11 月 3 日（星期一）支付。10 月 3 日（星期五）登记在册的股东将获得 0.62 美元的分红。这相当于每年 2.48 美元的分红，收益率为 5.6%。该分红的除息日为 10 月 3 日（星期五）。百时美施贵宝的分红支付比率目前为 100.00%。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人员买卖情况</h2>
</div><ul>
<li>Weak Guidance from Bristol-Myers Could Be Creating an Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>百时美施贵宝的疲软指引可能创造了机会</li>
</ul>
</div><p>In other news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the sale, the executive vice president owned 167,379 shares of the company's stock, valued at $7,922,048.07. This represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Insiders own 0.07% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，执行副总裁 David V. Elkins 在 9 月 2 日（星期二）出售了 56,000 股该股票。股票以平均价格 47.33 美元出售，总交易额为 2,650,480.00 美元。出售完成后，该执行副总裁持有 167,379 股公司股票，价值为 7,922,048.07 美元。这代表其持股减少了 25.07%。该交易已在向证券交易委员会的法律文件中披露，文件可通过此链接获取。内部人士持有公司 0.07% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several research firms have recently issued reports on BMY. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating and set a $42.00 price objective on the stock. in a report on Tuesday, August 5th. Daiwa America lowered shares of Bristol Myers Squibb from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, August 5th. Morgan Stanley reiterated a &#34;hold&#34; rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Citigroup decreased their target price on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a &#34;neutral&#34; rating on the stock in a research report on Friday, August 1st. Finally, Dbs Bank upgraded shares of Bristol Myers Squibb to a &#34;moderate buy&#34; rating in a research report on Thursday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and fifteen have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and an average price target of $57.14.</p>
<div class="lb-trans"><p>几家研究公司最近对 BMY 发布了报告。大和资本市场（Daiwa Capital Markets）将百时美施贵宝的股票评级从 “跑赢大盘” 下调至 “中性”，并设定了 42.00 美元的目标价。在 8 月 5 日（星期二）的报告中，大和美国（Daiwa America）将百时美施贵宝的股票评级从 “强烈买入” 下调至 “持有”。摩根士丹利（Morgan Stanley）在 7 月 31 日（星期四）的研究报告中重申了对百时美施贵宝的 “持有” 评级。花旗集团（Citigroup）在 8 月 1 日（星期五）的研究报告中将百时美施贵宝的目标价从 51.00 美元下调至 47.00 美元，并对该股票设定了 “中性” 评级。最后，Dbs Bank 在 10 月 2 日（星期四）的研究报告中将百时美施贵宝的股票评级上调至 “适度买入”。一位股票研究分析师对该股票给予了 “强烈买入” 评级，五位分析师给予 “买入” 评级，十五位分析师对该公司的股票给予 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，平均目标价为 57.14 美元。</p>
</div><p><strong>View Our Latest Report on BMY</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 BMY 的最新报告</strong></p>
</div><h2>Bristol Myers Squibb Profile</h2>
<div class="lb-trans"><h2>百时美施贵宝简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p>
<div class="lb-trans"><p>百时美施贵宝公司在全球范围内发现、开发、许可、制造、营销、分销和销售生物制药产品。它提供针对血液学、肿瘤学、心血管、免疫学、纤维化和神经科学疾病的产品。公司的产品包括 Eliquis，用于降低非瓣膜性房颤患者中风/全身栓塞的风险，以及治疗深静脉血栓/DVT/肺栓塞/PE；Opdivo，用于多种抗癌适应症，包括膀胱癌、血液癌、结直肠癌、头颈癌、肾细胞癌、肝细胞癌、肺癌、黑色素瘤、胸膜间皮瘤、胃癌和食道癌；Pomalyst/Imnovid 用于多发性骨髓瘤；Orencia 用于活动性类风湿关节炎和银屑病关节炎；Sprycel 用于治疗费城染色体阳性慢性髓性白血病。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Bristol Myers Squibb</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector</li>
<li>What is a Stock Market Index and How Do You Use Them?</li>
<li>These Are the 3 Hottest Sectors for Q3 Earnings Growth</li>
<li>Following Congress Stock Trades</li>
<li>AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比百时美施贵宝更好的股票</li>
<li>投资者最重要的沃伦·巴菲特股票：他自己的股票</li>
<li>EA 的 550 亿美元交易引发游戏行业的震荡</li>
<li>什么是股票市场指数，如何使用它们？</li>
<li>这些是第三季度盈利增长的三个热门行业</li>
<li>国会股票交易跟踪</li>
<li>AMD 可能会在此基础上翻倍——得益于其与 OpenAI 的重磅交易</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在百时美施贵宝吗？</h2>
</div><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑百时美施贵宝之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而百时美施贵宝并不在名单上。</p>
</div><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然百时美施贵宝目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

NBT Bank N A NY 减少了其在百时美施贵宝公司 $BMY 的持股